Allarity Therapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 15, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
(c) Issuer Purchases of Equity Securities
The following table provides information with respect to repurchases of shares of common stock by the Company during the three months ended June 30, 2025
| Period | Total Number of Shares Purchased | Average Price Paid per Share | Cumulative Shares Purchased as Part of Publicly Announced Plans | Dollar Value of Shares That May Yet Be Purchased Under the Plan |
|---|---|---|---|---|
| April, 2025 | 1,857,024 | $1.07 | 1,857,024 | $3,021,061 |
| May, 2025 | 99,242 | $1.12 | 1,956,266 | $2,865,074 |
| June, 2025 | 499,436 | $0.94 | 2,455,702 | $2,434,489 |
| Total | 2,455,702 | |||
On March 3, 2025, the Company’s board of directors approved the share repurchase program (the “Share Repurchase Program”), with authorization to purchase up to $5 million of the Company’s outstanding shares of common stock. Pursuant to the Share Repurchase Program, repurchases of the Company’s common stock were made through open market transactions or other methods as permitted by securities laws and regulations, including Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The Share Repurchase Program is authorized through February 28, 2026; however, the Company is not obligated to acquire any specific number of shares and may be modified, suspended, or discontinued at any time at the Company’s discretion.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.